Medizinische Universität Graz - Research portal
Selected Publication:
Mayer, R; Beham-Schmid, C; Groell, R; Smolle-Juettner, FM; Quehenberger, F; Stuecklschweiger, GF; Prettenhofer, U; Stranzl, H; Renner, H; Hackl, A.
Radiotherapy for invasive thymoma and thymic carcinoma. Clinicopathological review.
Strahlenther Onkol. 1999; 175(6):271-278
Doi: 10.1007/BF02743578
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Mayer Ramona
- Co-authors Med Uni Graz
- Beham-Schmid Christine
- Groell Reinhard
- Hackl Arnulf
- Prettenhofer Ulrike
- Quehenberger Franz
- Renner Heiko
- Smolle-Juettner Freyja-Maria
- Stranzl-Lawatsch Heidi
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: This study reports clinicopathological features and outcome of thymic tumors. Twenty-seven patients with invasive thymoma and 6 patients with thymic carcinoma who had received radiotherapy either primary or postoperatively were analyzed retrospectively. Patients and Methods: All 33 patients were irradiated with a mean dose of 50 Gy after complete resection (16 patients), partial resection (9 patients) or biopsy (8 patients). Staging was done according to the Masaoka classification; there were 12 Stage IT, 12 Stage III and 9 Stage IV patients. Results: In patients with invasive thymoma Stage II to IV (median follow-up 54.4 months) Kaplan-Meier estimates of overall survival (OS), disease-specific (DSS) and disease-free survival (DFS) at 5 years were 63.7% (95% confidence interval [CI], 42 to 84%), 88.3% (CI, 75 to 100%) and 77.4% (CI, 58 to 95%), respectively. Among the prognostic factors tested, such as age, myasthenia gravis, completeness of surgery and histologic subclassification, total radiation dose, and Masaoka Stage, the latter was the only significant predictor of improved survival (p = 0.04). Considering local control, radiation dose was a significant prognostic factor (p = 0.0006). In patients with thymic carcinoma (median follow-up 43.4 months) 5-year DSS, and DFS were 22.2% (CI, 0 to 60%) and 16.7% (CI, 0 to 46%), respectively. Thymoma as compared to thymic carcinoma had a statistically significant better DSS (p = 0.007) and DFS (p = 0.0007). Conclusion: Postoperative radiotherapy with sufficient doses plays an important role as adjuvant treatment in complete or incomplete resected invasive Stage II to III thymoma. In unresectable thymoma Stage III to IV as well as in thymic carcinoma a multimodality approach should be considered to improve survival.
- Find related publications in this database (using NLM MeSH Indexing)
- Actuarial Analysis -
- Adult -
- Aged -
- Biopsy -
- Combined Modality Therapy -
- Disease-Free Survival -
- Female -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Neoplasm Invasiveness -
- Neoplasm Staging -
- Radiotherapy Dosage -
- Retrospective Studies -
- Survival Analysis -
- Thymoma - mortality Thymoma - pathology Thymoma - radiotherapy Thymoma - surgery
- Thymus Neoplasms - mortality Thymus Neoplasms - pathology Thymus Neoplasms - radiotherapy Thymus Neoplasms - surgery
- Time Factors -
- Find related publications in this database (Keywords)
- invasive thymoma
- thymic carcinoma
- external radiotherapy
- prognostic factors